The Chinese Ministry of Health has found no clinical evidence to link Synutra’s infant milk products and premature breast growth in three infant girls.
Tests found no signs of inappropriate hormones and the Ministry said yesterday (15 August) that, when looking at similar cases of precocious puberty in recent years, there was no heightened risk of being affected through using infant formula compared to breast feeding.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The move follows a week of speculation in the Chinese media that hormones in infant formula from Chinese firm Synutra was responsible for the early development. Synutra has vehemently defended the safety of its products.
The Ministry said it did not find any unusual levels of hormones in the 73 samples it tested, of which 42 were Synutra’s milk, and one sample of milk residue from one of the infants’ homes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
